{
  "id": 9321589,
  "title": "AC Immune reports positive phase 2 trial results for ACI-7104",
  "url": "https://urgent.news/2026/09/23/ac-immune-reports-positive-phase-2-trial-results-for-aci-7104",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-23T11:12:39.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/ac-immune-reports-positive-phase-2-trial-results-for-aci7104-93CH-4912714"
  },
  "original_language": "en",
  "account": "LAUSANNE, Switzerland - AC Immune SA revealed promising phase 2 trial results for ACI-7104, an active immunotherapy targeting alpha-synuclein protein aggregates, which contribute to neuron degeneration in Parkinson's disease. In Part 1 of the VacSYn trial, 34 patients received ACI-7104 or a placebo, with all patients generating antibodies against the target antigen following three immunizations. The treatment was deemed safe and well-tolerated. Antibody penetration into cerebrospinal fluid was observed in all participants, and a signal was noted for total alpha-synuclein reactivity in the fluid, indicating potential target engagement. While Part 1 did not evaluate biomarker or clinical outcomes, exploratory analyses suggested a potential link between antibody levels and disease activity measures. The trial will extend for two years before advancing to Part 2, designed to provide clinical activity evidence for a phase 3 decision. AC Immune, a clinical-stage biopharmaceutical company, has partnerships valued at over $4.5 billion in potential milestone payments and royalties.",
  "summary": null,
  "key_points": [
    "AC Immune's phase 2 trial shows ACI-7104 generates antibodies against alpha-synuclein.",
    "Treatment is safe and well-tolerated in all 34 patients.",
    "Exploratory data suggests potential link between antibodies and disease activity."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "AC Immune spikes after mid-stage trial data for Parkinson’s drug",
        "url": "https://urgent.news/2026/09/23/ac-immune-spikes-after-mid-stage-trial-data-for-parkinsons-drug",
        "published": "2026-09-23T11:52:42.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}